{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T21:07:09Z","timestamp":1784668029631,"version":"3.55.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione e del Merito","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-025-04142-w","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T15:46:07Z","timestamp":1766504767000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Darunavir analog precursors target mitochondrial metabolism in multiple myeloma and CLL."],"prefix":"10.1186","volume":"26","author":[{"given":"Marisabel","family":"Mecca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Sichetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico La","family":"Spina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Giuseffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Giglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Picerno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Valvano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Statuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Santarsiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Funicello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Francesca","family":"Armentano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Chiummiento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Lupattelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Cortellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"4142_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052750","volume":"25","author":"M Mecca","year":"2024","unstructured":"Mecca M, Picerno S, Cortellino S. The killer\u2019s web: interconnection between inflammation, epigenetics and nutrition in cancer. Int J Mol Sci. 2024;25:2750.","journal-title":"Int J Mol Sci"},{"key":"4142_CR2","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.3390\/cancers15153898","volume":"15","author":"S Cortellino","year":"2023","unstructured":"Cortellino S, Longo VD. Metabolites and immune response in tumor microenvironments. Cancers. 2023;15:3898.","journal-title":"Cancers"},{"key":"4142_CR3","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrc3038","volume":"11","author":"WH Koppenol","year":"2011","unstructured":"Koppenol WH, Bounds PL, Dang CV. Otto warburg\u2019s contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11:325\u201337.","journal-title":"Nat Rev Cancer"},{"key":"4142_CR4","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ccell.2023.02.012","volume":"41","author":"D Hanahan","year":"2023","unstructured":"Hanahan D, Monje M. Cancer hallmarks intersect with neuroscience in the tumor microenvironment. Cancer Cell. 2023;41:573\u201380.","journal-title":"Cancer Cell"},{"key":"4142_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.cmet.2011.12.015","volume":"15","author":"MO Yuneva","year":"2012","unstructured":"Yuneva MO, Fan TWM, Allen TD, Higashi RM, Ferraris DV, Tsukamoto T, et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 2012;15:157\u201370.","journal-title":"Cell Metab"},{"key":"4142_CR6","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1126\/science.aaf5171","volume":"353","author":"JR Mayers","year":"2016","unstructured":"Mayers JR, Torrence ME, Danai LV, Papagiannakopoulos T, Davidson SM, Bauer MR, et al. Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras -driven cancers. Science. 2016;353:1161\u20135.","journal-title":"Science"},{"key":"4142_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.31417","volume":"240","author":"S Cortellino","year":"2025","unstructured":"Cortellino S, D\u2019Angelo M, Quintiliani M, Giordano A. Cancer knocks you out by fasting: cachexia as a consequence of metabolic alterations in cancer. J Cell Physiol. 2025;240:e31417.","journal-title":"J. Cell. Physiol."},{"key":"4142_CR8","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1158\/0008-5472.CAN-18-0773","volume":"79","author":"CR Marlein","year":"2019","unstructured":"Marlein CR, Piddock RE, Mistry JJ, Zaitseva L, Hellmich C, Horton RH, et al. CD38-Driven Mitochondrial Trafficking Promotes Bioenergetic Plasticity in Multiple Myeloma. Cancer Res. 2019;79:2285\u201397.","journal-title":"Cancer Res"},{"key":"4142_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau9087","volume":"11","author":"H Liu","year":"2019","unstructured":"Liu H, He J, Koh SP, Zhong Y, Liu Z, Wang Z, et al. Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease. Sci Transl Med. 2019;11:eaau9087.","journal-title":"Sci Transl Med"},{"key":"4142_CR10","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1182\/blood-2013-10-532200","volume":"123","author":"R Jitschin","year":"2014","unstructured":"Jitschin R, Hofmann AD, Bruns H, Gie\u00dfl A, Bricks J, Berger J, et al. Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia. Blood. 2014;123:2663\u201372.","journal-title":"Blood"},{"key":"4142_CR11","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s00277-023-05590-y","volume":"103","author":"B Pan","year":"2024","unstructured":"Pan B, Xu Z, Du K, Gao R, Zhang J, Yin H, et al. Investigation of fatty acid metabolism in chronic lymphocytic leukemia to guide clinical outcome and therapy. Ann Hematol. 2024;103:1241\u201354.","journal-title":"Ann Hematol"},{"key":"4142_CR12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41590-020-0598-4","volume":"21","author":"FJ Weisel","year":"2020","unstructured":"Weisel FJ, Mullett SJ, Elsner RA, Menk AV, Trivedi N, Luo W, et al. Germinal center B cells selectively oxidize fatty acids for energy while conducting minimal glycolysis. Nat Immunol. 2020;21:331\u201342.","journal-title":"Nat Immunol"},{"key":"4142_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40170-020-00235-4","volume":"8","author":"WI Gonsalves","year":"2020","unstructured":"Gonsalves WI, Jang JS, Jessen E, Hitosugi T, Evans LA, Jevremovic D, et al. In vivo assessment of glutamine anaplerosis into the TCA cycle in human pre-malignant and malignant clonal plasma cells. Cancer Metab. 2020;8:29.","journal-title":"Cancer Metab"},{"key":"4142_CR14","doi-asserted-by":"publisher","first-page":"5663","DOI":"10.1038\/onc.2016.103","volume":"35","author":"PP Liu","year":"2016","unstructured":"Liu PP, Liu J, Jiang WQ, Carew JS, Ogasawara MA, Pelicano H, et al. Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline. Oncogene. 2016;35:5663\u201373.","journal-title":"Oncogene"},{"key":"4142_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.604143","volume":"10","author":"A Barbato","year":"2020","unstructured":"Barbato A, Scandura G, Puglisi F, Cambria D, La Spina E, Palumbo GA, et al. Mitochondrial bioenergetics at the onset of drug resistance in hematological malignancies: an overview. Front Oncol. 2020;10:604143.","journal-title":"Front Oncol"},{"key":"4142_CR16","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1007\/s12015-025-10956-y","volume":"21","author":"LQ Keoh","year":"2025","unstructured":"Keoh LQ, Chiu CF, Ramasamy TS. Metabolic plasticity and cancer stem cell metabolism: exploring the glycolysis-OXPHOS switch as a mechanism for resistance and tumorigenesis. Stem Cell Rev Rep. 2025;21:2446\u201368.","journal-title":"Stem Cell Rev Rep"},{"key":"4142_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40164-022-00292-z","volume":"11","author":"Y Nie","year":"2022","unstructured":"Nie Y, Yun X, Zhang Y, Wang X. Targeting metabolic reprogramming in chronic lymphocytic leukemia. Exp Hematol Oncol. 2022;11:39.","journal-title":"Exp Hematol Oncol"},{"key":"4142_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1007","volume":"7","author":"N Nikesitch","year":"2018","unstructured":"Nikesitch N, Lee JM, Ling S, Roberts TL. Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance. Clinical & Translational Immunology. 2018;7:e1007.","journal-title":"Clinical & Translational Immunology"},{"key":"4142_CR19","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.trecan.2020.05.012","volume":"6","author":"A Khateb","year":"2020","unstructured":"Khateb A, Ronai ZA. Unfolded protein response in leukemia: from basic understanding to therapeutic opportunities. Trends Cancer. 2020;6:960\u201373.","journal-title":"Trends Cancer"},{"key":"4142_CR20","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1182\/blood-2014-05-578732","volume":"124","author":"LH Boise","year":"2014","unstructured":"Boise LH, Kaufman JL, Bahlis NJ, Lonial S, Lee KP. The tao of myeloma. Blood. 2014;124:1873\u20139.","journal-title":"Blood"},{"key":"4142_CR21","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1182\/blood-2018-01-791376","volume":"131","author":"D Rossi","year":"2018","unstructured":"Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood. 2018;131:2761\u201372.","journal-title":"Blood"},{"key":"4142_CR22","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1038\/s41467-020-15051-z","volume":"11","author":"R Bajpai","year":"2020","unstructured":"Bajpai R, Sharma A, Achreja A, Edgar CL, Wei C, Siddiqa AA, et al. Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. Nat Commun. 2020;11:1228.","journal-title":"Nat Commun"},{"key":"4142_CR23","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.3324\/haematol.2018.207704","volume":"104","author":"L Besse","year":"2019","unstructured":"Besse L, Besse A, Mendez-Lopez M, Vasickova K, Sedlackova M, Vanhara P, et al. A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis. Haematologica. 2019;104:e415\u20139.","journal-title":"Haematologica"},{"key":"4142_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1039\/D1MO00106J","volume":"18","author":"EA Zaal","year":"2022","unstructured":"Zaal EA, De Grooth HJ, Oudaert I, Langerhorst P, Levantovsky S, Van Slobbe GJJ, et al. Targeting coenzyme Q10 synthesis overcomes bortezomib resistance in multiple myeloma. Mol Omics. 2022;18:19\u201330.","journal-title":"Mol. Omics"},{"key":"4142_CR25","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1182\/blood.2021013990","volume":"140","author":"Z Chen","year":"2022","unstructured":"Chen Z, Simon-Molas H, Cretenet G, Valle-Argos B, Smith LD, Forconi F, et al. Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment. Blood. 2022;140:630\u201343.","journal-title":"Blood"},{"key":"4142_CR26","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1158\/0008-5472.CAN-22-2350","volume":"83","author":"KL Burger","year":"2023","unstructured":"Burger KL, Fernandez MR, Meads MB, Sudalagunta P, Oliveira PS, Renatino Canevarolo R, et al. CK1\u03b4 and CK1\u03b5 signaling sustains mitochondrial metabolism and cell survival in multiple myeloma. Cancer Res. 2023;83:3901\u201319.","journal-title":"Cancer Res"},{"key":"4142_CR27","doi-asserted-by":"publisher","first-page":"6432","DOI":"10.1158\/1078-0432.CCR-21-2040","volume":"27","author":"JM Waldschmidt","year":"2021","unstructured":"Waldschmidt JM, Kloeber JA, Anand P, Frede J, Kokkalis A, Dimitrova V, et al. Single-Cell profiling reveals metabolic reprogramming as a resistance mechanism in BRAF -Mutated multiple myeloma. Clin Cancer Res. 2021;27:6432\u201344.","journal-title":"Clin Cancer Res"},{"key":"4142_CR28","doi-asserted-by":"publisher","first-page":"375","DOI":"10.5694\/mja2.50129","volume":"210","author":"DE Joshua","year":"2019","unstructured":"Joshua DE, Bryant C, Dix C, Gibson J, Ho J. Biology and therapy of multiple myeloma. Med J Aust. 2019;210:375\u201380.","journal-title":"Med J Aust"},{"key":"4142_CR29","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1158\/2159-8290.CD-NB2022-0019","volume":"12","author":"Cilta-cel","year":"2022","unstructured":"Cilta-cel. OK\u2019d for multiple myeloma. Cancer Discov. 2022;12:1176\u20131176.","journal-title":"Cancer Discov"},{"key":"4142_CR30","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1182\/asheducation-2015.1.368","volume":"2015","author":"S Stilgenbauer","year":"2015","unstructured":"Stilgenbauer S. Prognostic markers and standard management of chronic lymphocytic leukemia. Hematology. 2015;2015:368\u201377.","journal-title":"Hematology"},{"key":"4142_CR31","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1038\/sj.bjc.6603435","volume":"95","author":"Y Yang","year":"2006","unstructured":"Yang Y, Ikezoe T, Nishioka C, Bandobashi K, Takeuchi T, Adachi Y, et al. NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines. Br J Cancer. 2006;95:1653\u201362.","journal-title":"Br J Cancer"},{"key":"4142_CR32","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1158\/1078-0432.CCR-05-1167","volume":"12","author":"A Srirangam","year":"2006","unstructured":"Srirangam A, Mitra R, Wang M, Gorski JC, Badve S, Baldridge L, et al. Effects of HIV protease inhibitor Ritonavir on Akt-Regulated cell proliferation in breast cancer. Clin Cancer Res. 2006;12:1883\u201396.","journal-title":"Clin Cancer Res"},{"key":"4142_CR33","first-page":"5230","volume":"62","author":"F Pajonk","year":"2002","unstructured":"Pajonk F, Himmelsbach J, Riess K, Sommer A, McBride WH. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res. 2002;62:5230\u20135.","journal-title":"Cancer Res"},{"key":"4142_CR34","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/1535-7163.473.3.4","volume":"3","author":"T Ikezoe","year":"2004","unstructured":"Ikezoe T, Saito T, Bandobashi K, Yang Y, Koeffler HP, Taguchi H. HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1\/2. Mol Cancer Ther. 2004;3:473\u20139.","journal-title":"Mol Cancer Ther"},{"key":"4142_CR35","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1158\/0008-5472.CAN-06-3377","volume":"67","author":"W Jiang","year":"2007","unstructured":"Jiang W, Mikochik PJ, Ra JH, Lei H, Flaherty KT, Winkler JD, et al. HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest. Cancer Res. 2007;67:1221\u20137.","journal-title":"Cancer Res"},{"key":"4142_CR36","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1476-4598-8-26","volume":"8","author":"S Kumar","year":"2009","unstructured":"Kumar S, Bryant CS, Chamala S, Qazi A, Seward S, Pal J, et al. Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells. Mol Cancer. 2009;8:26.","journal-title":"Mol Cancer"},{"key":"4142_CR37","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/j.1349-7006.2005.00063.x","volume":"96","author":"Y Yang","year":"2005","unstructured":"Yang Y, Ikezoe T, Takeuchi T, Adachi Y, Ohtsuki Y, Takeuchi S, et al. HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling. Cancer Sci. 2005;96:425\u201333.","journal-title":"Cancer Sci"},{"key":"4142_CR38","doi-asserted-by":"publisher","first-page":"8256","DOI":"10.1158\/0008-5472.CAN-05-1220","volume":"65","author":"AK Gupta","year":"2005","unstructured":"Gupta AK, Cerniglia GJ, Mick R, McKenna WG, Muschel RJ. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both In vitro and In vivo. Cancer Res. 2005;65:8256\u201365.","journal-title":"Cancer Res"},{"key":"4142_CR39","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.radonc.2013.03.023","volume":"107","author":"J Buijsen","year":"2013","unstructured":"Buijsen J, Lammering G, Jansen RLH, Beets GL, Wals J, Sosef M, et al. Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer. Radiother Oncol. 2013;107:184\u20138.","journal-title":"Radiother Oncol"},{"key":"4142_CR40","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3324\/haematol.2015.135780","volume":"101","author":"C Driessen","year":"2016","unstructured":"Driessen C, Kraus M, Joerger M, Rosing H, Bader J, Hitz F, et al. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65\/08). Haematologica. 2016;101:346\u201355.","journal-title":"Haematologica"},{"key":"4142_CR41","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1158\/1078-0432.CCR-07-0161","volume":"13","author":"JJ Gills","year":"2007","unstructured":"Gills JJ, LoPiccolo J, Tsurutani J, Shoemaker RH, Best CJM, Abu-Asab MS, et al. Nelfinavir, A lead HIV protease inhibitor, is a Broad-Spectrum, anticancer agent that induces Endoplasmic reticulum Stress, Autophagy, and apoptosis In vitro and In vivo. Clin Cancer Res. 2007;13:5183\u201394.","journal-title":"Clin Cancer Res"},{"key":"4142_CR42","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/nrc1479","volume":"4","author":"P Monini","year":"2004","unstructured":"Monini P, Sgadari C, Toschi E, Barillari G, Ensoli B. Antitumour effects of antiretroviral therapy. Nat Rev Cancer. 2004;4:861\u201375.","journal-title":"Nat Rev Cancer"},{"key":"4142_CR43","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nm0302-225","volume":"8","author":"C Sgadari","year":"2002","unstructured":"Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med. 2002;8:225\u201332.","journal-title":"Nat Med"},{"key":"4142_CR44","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1182\/blood-2018-05-851170","volume":"132","author":"C Driessen","year":"2018","unstructured":"Driessen C, M\u00fcller R, Novak U, Cantoni N, Betticher D, Mach N, et al. Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor\u2013refractory multiple myeloma. Blood. 2018;132:2097\u2013100.","journal-title":"Blood"},{"key":"4142_CR45","first-page":"615","volume":"17","author":"M Mendez-Lopez","year":"2019","unstructured":"Mendez-Lopez M, Sutter T, Driessen C, Besse L. HIV protease inhibitors for the treatment of multiple myeloma. Clin Adv Hematol Oncol. 2019;17:615\u201323.","journal-title":"Clin Adv Hematol Oncol"},{"key":"4142_CR46","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.3390\/cells10113052","volume":"10","author":"R Rinaldi","year":"2021","unstructured":"Rinaldi R, Miglionico R, Nigro I, D\u2019Orsi R, Chiummiento L, Funicello M, et al. Two novel precursors of the HIV-1 protease inhibitor Darunavir target the UPR\/Proteasome system in human hepatocellular carcinoma cell line HepG2. Cells. 2021;10:3052.","journal-title":"Cells"},{"key":"4142_CR47","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1016\/j.bmc.2019.03.041","volume":"27","author":"F Tramutola","year":"2019","unstructured":"Tramutola F, Armentano MF, Berti F, Chiummiento L, Lupattelli P, D\u2019Orsi R, et al. New heteroaryl carbamates: synthesis and biological screening in vitro and in mammalian cells of wild-type and mutant HIV-protease inhibitors. Bioorg Med Chem. 2019;27:1863\u201370.","journal-title":"Bioorg Med Chem"},{"key":"4142_CR48","doi-asserted-by":"crossref","unstructured":"Methods to Monitor ROS Production by Fluorescence Microscopy and Fluorometry [Internet]. In: Methods in Enzymology. Elsevier. 2014 [cited 2025 Oct 30]. page 243\u201362.Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780124166189000133","DOI":"10.1016\/B978-0-12-416618-9.00013-3"},{"key":"4142_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2021.100466","volume":"2","author":"Y Yang","year":"2021","unstructured":"Yang Y, Zhang G, Yang T, Gan J, Xu L, Yang H. A flow-cytometry-based protocol for detection of mitochondrial ROS production under hypoxia. STAR Protoc. 2021;2:100466.","journal-title":"STAR Protoc"},{"key":"4142_CR50","doi-asserted-by":"publisher","first-page":"10920","DOI":"10.1158\/0008-5472.CAN-07-0796","volume":"67","author":"P Pyrko","year":"2007","unstructured":"Pyrko P, Kardosh A, Wang W, Xiong W, Sch\u00f6nthal AH, Chen TC. HIV-1 protease inhibitors nelfinavir and Atazanavir induce malignant glioma death by triggering Endoplasmic reticulum stress. Cancer Res. 2007;67:10920\u20138.","journal-title":"Cancer Res"},{"key":"4142_CR51","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/s41416-024-02774-9","volume":"131","author":"A Besse","year":"2024","unstructured":"Besse A, Sedlarikova L, Buechler L, Kraus M, Yang CH, Strakova N, et al. HIV-protease inhibitors potentiate the activity of Carfilzomib in triple-negative breast cancer. Br J Cancer. 2024;131:918\u201330.","journal-title":"Br J Cancer"},{"key":"4142_CR52","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1080\/15548627.2024.2325304","volume":"20","author":"Y Wu","year":"2024","unstructured":"Wu Y, Chen Y, Yan X, Dai X, Liao Y, Yuan J, et al. Lopinavir enhances Anoikis by remodeling autophagy in a circRNA-dependent manner. Autophagy. 2024;20:1651\u201372.","journal-title":"Autophagy"},{"key":"4142_CR53","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.3324\/haematol.2011.049981","volume":"97","author":"C Bono","year":"2012","unstructured":"Bono C, Karlin L, Harel S, Mouly E, Labaume S, Galicier L, et al. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo. Haematologica. 2012;97:1101\u20139.","journal-title":"Haematologica"},{"key":"4142_CR54","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.canlet.2015.04.027","volume":"364","author":"T Xiang","year":"2015","unstructured":"Xiang T, Du L, Pham P, Zhu B, Jiang S. Nelfinavir, an HIV protease inhibitor, induces apoptosis and cell cycle arrest in human cervical cancer cells via the ROS-dependent mitochondrial pathway. Cancer Lett. 2015;364:79\u201388.","journal-title":"Cancer Lett"},{"key":"4142_CR55","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00044-014-1143-5","volume":"24","author":"V Facchinetti","year":"2015","unstructured":"Facchinetti V, Moreth M, Gomes CRB, Do \u00d3, Pessoa C, Rodrigues FAR, Cavalcanti BC, et al. Evaluation of (2S,3R)-2-(amino)-[4-(N-benzylarenesulfonamido)-3-hydroxy-1-phenylbutane derivatives: a promising class of anticancer agents. Med Chem Res. 2015;24:533\u201342.","journal-title":"Med Chem Res"},{"key":"4142_CR56","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1038\/s41467-022-31248-w","volume":"13","author":"J Xia","year":"2022","unstructured":"Xia J, Zhang J, Wu X, Du W, Zhu Y, Liu X, et al. Blocking Glycine utilization inhibits multiple myeloma progression by disrupting glutathione balance. Nat Commun. 2022;13:4007.","journal-title":"Nat Commun"},{"key":"4142_CR57","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s42255-019-0108-x","volume":"1","author":"FF Diehl","year":"2019","unstructured":"Diehl FF, Lewis CA, Fiske BP, Vander Heiden MG. Cellular redox state constrains Serine synthesis and nucleotide production to impact cell proliferation. Nat Metab. 2019;1:861\u20137.","journal-title":"Nat Metab"},{"key":"4142_CR58","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41375-023-02095-5","volume":"38","author":"H Playa-Albinyana","year":"2024","unstructured":"Playa-Albinyana H, Arenas F, Royo R, Gir\u00f3 A, L\u00f3pez-Oreja I, Aymerich M, et al. Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation. Leukemia. 2024;38:557\u201369.","journal-title":"Leukemia"},{"key":"4142_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02311-x","volume":"10","author":"H Du","year":"2025","unstructured":"Du H, Xu T, Yu S, Wu S, Zhang J. Mitochondrial metabolism and cancer therapeutic innovation. Signal Transduct Target Ther. 2025;10:245.","journal-title":"Signal Transduct. Target. Ther"},{"key":"4142_CR60","first-page":"115","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, et al. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat. Med. 2023;29:115\u201326.","journal-title":"Med"},{"key":"4142_CR61","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2049-3002-2-4","volume":"2","author":"SD Stuart","year":"2014","unstructured":"Stuart SD, Schauble A, Gupta S, Kennedy AD, Keppler BR, Bingham PM, et al. A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process. Cancer Metab. 2014;2:4.","journal-title":"Cancer Metab"},{"key":"4142_CR62","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1158\/0008-5472.CAN-22-0042","volume":"82","author":"Y Li","year":"2022","unstructured":"Li Y, Li B, Xu Y, Qian L, Xu T, Meng G, et al. GOT2 silencing promotes reprogramming of glutamine metabolism and sensitizes hepatocellular carcinoma to glutaminase inhibitors. Cancer Res. 2022;82:3223\u201335.","journal-title":"Cancer Res"},{"key":"4142_CR63","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10549-018-05070-2","volume":"174","author":"MYME investigators","year":"2019","unstructured":"investigators MYME, Nanni O, Amadori D, De Censi A, Rocca A, Freschi A, et al. Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial. Breast Cancer Res Treat. 2019;174:433\u201342.","journal-title":"Breast Cancer Res Treat"},{"key":"4142_CR64","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1001\/jama.2022.6147","volume":"327","author":"PJ Goodwin","year":"2022","unstructured":"Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, et al. Effect of Metformin vs placebo on invasive disease\u2013free survival in patients with breast cancer: the MA.32 randomized clinical trial. JAMA. 2022;327:1963.","journal-title":"JAMA"},{"key":"4142_CR65","doi-asserted-by":"publisher","first-page":"e192553","DOI":"10.1001\/jamaoncol.2019.2553","volume":"5","author":"O Arrieta","year":"2019","unstructured":"Arrieta O, Barr\u00f3n F, Padilla M\u00c1S, Avil\u00e9s-Salas A, Ram\u00edrez-Tirado LA, Arguelles Jim\u00e9nez MJ, et al. Effect of Metformin plus tyrosine kinase inhibitors compared with tyrosine kinase inhibitors alone in patients with epidermal growth factor Receptor\u2013Mutated lung adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2019;5:e192553.","journal-title":"JAMA Oncol"},{"key":"4142_CR66","doi-asserted-by":"crossref","unstructured":"Brown JR, Chan DK, Shank JJ, Griffith KA, Fan H, Szulawski R et al. Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer. JCI Insight [Internet] 2020 [cited 2025 Nov 6];Available from: http:\/\/insight.jci.org\/articles\/view\/133247","DOI":"10.1172\/jci.insight.133247"},{"key":"4142_CR67","doi-asserted-by":"publisher","first-page":"vi228","DOI":"10.1093\/annonc\/mdw371.67","volume":"27","author":"AT Alistar","year":"2016","unstructured":"Alistar AT, Desnoyers R, D\u2019Agostino RJ, Pasche B. CPI-613 enhances FOLFIRINOX response rate in stage IV pancreatic cancer. Ann Oncol. 2016;27:vi228.","journal-title":"Ann Oncol"},{"key":"4142_CR68","first-page":"5255","volume":"20","author":"TS Pardee","year":"2014","unstructured":"Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, et al. A phase I study of the First-in-Class antimitochondrial metabolism Agent, CPI-613, in patients with advanced hematologic Malignancies. Clin. Cancer Res. 2014;20:5255\u201364.","journal-title":"Cancer Res"},{"key":"4142_CR69","doi-asserted-by":"publisher","first-page":"100009","DOI":"10.1016\/j.bneo.2024.100009","volume":"1","author":"TS Pardee","year":"2024","unstructured":"Pardee TS, Powell BL, Larson RA, Maly J, Keng M, Foster M, et al. Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trial. Blood Neoplasia. 2024;1:100009.","journal-title":"Blood Neoplasia"},{"key":"4142_CR70","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1200\/JCO.23.02659","volume":"42","author":"PA Philip","year":"2024","unstructured":"Philip PA, Sahai V, Bahary N, Mahipal A, Kasi A, Rocha Lima CMS, et al. Devimistat (CPI-613) with modified Fluorouarcil, Oxaliplatin, Irinotecan, and leucovorin (FFX) versus FFX for patients with metastatic adenocarcinoma of the pancreas: the phase III AVENGER 500 study. J Clin Oncol. 2024;42:3692\u2013701.","journal-title":"J Clin Oncol"},{"key":"4142_CR71","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/15284336.2017.1408928","volume":"19","author":"A Jackson","year":"2018","unstructured":"Jackson A, Else L, Higgs C, Karolia Z, Khoo S, Back D, et al. Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir\/ritonavir in treatment-na\u00efve HIV-1-infected individuals. HIV Clin Trials. 2018;19:31\u20137.","journal-title":"HIV Clin Trials"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-025-04142-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-04142-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-04142-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T17:02:20Z","timestamp":1769446940000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-025-04142-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4142"],"URL":"https:\/\/doi.org\/10.1186\/s12935-025-04142-w","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All human samples used in this study were obtained with the approval of the Ethics Committee of Policlinico Catania 1, (ID: n.34\/2019\/PO).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patients\/participants provided their written informed consent to participate in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}